Report of FDA Approved Commercial Products Involving NIH Extramural Support

Items listed on this page have been identified as having involved NIH extramural support that helped to further the research and development of these final products. Although each product may have multiple funding sources and may include multiple technologies, the products are listed because NIH extramural support was also identified as being involved.

Please note that the time for development of a successful FDA approved drug, from basic research and initial identification of a potential candidate compound through to FDA approval, can range from 5 years to 15 years.

Commercial NameFDA Approval TypeFDA Approval NumberNIH Support
Active Contact System HD036154
BexxarBiologicBL 125011/0CA042768
BiologicBL 125011/0CA056794
Estramet CA022795
FluMistBiologicBL 125020/43AI005053
BiologicBL 125020/43AI052564
BiologicBL 125020/43AI072521
GEMS 21Medical DeviceP040013DE007010
LyricaDrug021446NS015703
MenostarDrugNDA# 021674AG005407
ONTAKBiologic1258AI012500
Biologic1258AM016684
ProKera (TM)Medical DeviceK032104R01 EY006819
RestasisDrug50-790EY005720
Trusopt & Cosopt EY002227
ZolinzaDrugNDA 21-991CA057227


Commercial NameSupport
EmtrivaAI026055
AI028731
Epogen
KaletraAI027220
Neupogen
NorvirAI027220
Procrit
Taxol
TruvadaAI026055
AI028731
XalatanEY000333
EY000402
ZeritCA028852

Home | About | Help
E-mail the NIH administrator | OMB Burden Statement | iEdison Privacy Notice